临床试验/NCT05224492

NCT05224492Unknown4 期

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Sunshine Specialty Health Care0 个研究点目标入组 20 人开始时间: 2022年2月21日最近更新: 2022年2月7日

适应症

干预措施

试验速览

阶段: 4 期
发起方
入组人数: 20
主要终点: Lipids

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Single (Participant)

入排标准

年龄范围: 18 Years 至 85 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more.
•BMI increase of 10% or more since initiation of HIV treatment over a year period.
•BMI equal to or greater than
•18-85 years of age.

排除标准

•Pregnancy or breastfeeding
•Intolerance to cruciferous vegetables
•Intolerance to sulforaphane
•Gluten Intolerance
•Creatinine > 1.3 mg/dL
•GFR < 60
•AST or ALT > 1.5 times upper limit of normal.
•White cell count < 2000 cells per ml.
•Hemoglobin < 10.5 g/dL.
•Platelet count < 140,000 per ml.

研究组 & 干预措施

Sulforaphane Group

Experimental

干预措施: Sulforaphane (Drug)

Placebo Group

Placebo Comparator

干预措施: Placebo (Other)

结局指标

主要结局

Lipids

时间窗: 4 months

Triglycerides, Cholesterol

Inflammatory Markers

时间窗: 4 months

CRP

次要结局

未报告次要终点

研究者

发起方

Sunshine Specialty Health Care

申办方类型

Other

责任方

Sponsor

相似试验

已完成

不适用

Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDSHIV Infections

NCT03141918Universidade Federal do Rio Grande do Norte20

已完成

不适用

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIVHIV InfectionsAtherosclerosis

NCT00575939University Hospitals Cleveland Medical Center120

已完成

2 期

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV TherapyHIV Infections

NCT00000850National Institute of Allergy and Infectious Diseases (NIAID)108

已完成

4 期

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male VolunteersHIV Infections

NCT00648817Gilead Sciences8

Unknown

不适用

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive PatientsCardiovascular DiseaseHIV Infections

NCT01066065Hospital Carlos III, Madrid120